GlassScriptPhysician profile
Mary Vath
NPI 1811545338
$5,133.75
in general payments reported to CMS, 2019-2025
30 companies · $852 in 2025
The $852 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $1,143 · 2023: $1,003 · 2024: $1,040 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,894.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,119.82 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $747.90 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $543.13 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $466.60 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $405.76 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.72 | 2022-2024 | Jardiance |
| Pfizer INC. | $189.07 | 2021-2025 | |
| Scpharmaceuticals INC. | $151.32 | 2024-2025 | |
| Boston Scientific Corporation | $141.06 | 2022-2025 | Watchman Flx |
| Chiesi USA, INC. | $138.97 | 2021-2025 | Cleviprex, Kengreal, Curosurf |
| Astrazeneca Pharmaceuticals LP | $131.53 | 2021-2023 | Farxiga |
| Endologix LLC | $102.00 | 2022 | |
| Endotronix, INC. | $92.20 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Esperion Therapeutics, INC. | $92.19 | 2021-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $82.89 | 2021-2025 | Camzyos, Eliquis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $75.54 | 2023-2024 | |
| Abbott Laboratories | $71.08 | 2025 | Cardiomems |
| Cvrx, INC. | $54.49 | 2023-2024 | Barostim Neo System |
| Novo Nordisk INC | $53.57 | 2024-2025 | Wegovy, Ozempic |
| Lexicon Pharmaceuticals, INC. | $37.17 | 2024 | |
| Argon Medical Devices, INC. | $32.27 | 2025 | Clot Management |
| Amarin Pharma, INC. | $32.06 | 2021-2022 | |
| Recor Medical INC | $31.44 | 2025 | Paradise Ultrasound Renal Denervation System |
| Cook Medical LLC | $28.86 | 2021 | |
| Inspire Medical Systems, INC. | $26.77 | 2023 | Inspire |
| Tactile Systems Technology INC | $22.01 | 2023 | Flexitouch Plus, Entre Plus |
| Vifor Pharma, INC. | $17.62 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $16.82 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $14.18 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Vath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.